These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
561 related articles for article (PubMed ID: 18070713)
1. Thalidomide in the treatment of multiple myeloma. Kastritis E; Dimopoulos MA Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713 [TBL] [Abstract][Full Text] [Related]
2. Lenalidomide in multiple myeloma. Thomas SK; Richards TA; Weber DM Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715 [TBL] [Abstract][Full Text] [Related]
3. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
4. The role of thalidomide in multiple myeloma. Schwab C; Jagannath S Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766 [TBL] [Abstract][Full Text] [Related]
6. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. Mariz JM; Esteves GV Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806 [TBL] [Abstract][Full Text] [Related]
7. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
8. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P Oncology; 2006; 70(6):474-82. PubMed ID: 17283449 [TBL] [Abstract][Full Text] [Related]
9. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related]
10. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Steurer M; Spizzo G; Mitterer M; Gastl G Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347 [TBL] [Abstract][Full Text] [Related]
16. Lenalidomide: an update on evidence from clinical trials. Dimopoulos MA; Terpos E Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633 [TBL] [Abstract][Full Text] [Related]
17. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347 [TBL] [Abstract][Full Text] [Related]
18. [Thalidomide with or without dexamethasone for refractory multiple myeloma]. Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Therapie; 2002; 57(6):524-9. PubMed ID: 12666259 [TBL] [Abstract][Full Text] [Related]
19. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105 [TBL] [Abstract][Full Text] [Related]
20. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]